Daewoong Pharmaceutical(069620)'s in-house–developed botulinum toxin "Nabota" has surpassed 1 trillion won in cumulative sales. It has been 12 years since its domestic launch in 2014.
According to Daewoong Pharmaceutical on the 13th, Nabota's cumulative sales surpassed 1 trillion won as of the end of June.
Nabota grew mainly in overseas markets after becoming the first among Asian botulinum toxins to receive product approval from the U.S. Food and Drug Administration (FDA) in 2019. From 2019 to 2025, its compound annual sales growth rate came to 57%, and last year it surpassed 200 billion won in annual sales for the first time as a single item.
Currently, Nabota is sold under the brand "Nabota" in the United States and global markets, "Jeuveau" in the United States, and "Nuceiva" in Europe. Following the U.S. FDA, it also obtained approvals from major regulators such as the European Medicines Agency (EMA) and Health Canada.
In the United States, it is supplied through partner Evolus. Daewoong Pharmaceutical said it is expanding sales into Latin America, Southeast Asia, and the Middle East and North Africa, adding that it has partnerships with about 80 countries and has obtained product approvals in 69 countries.
The company is also building a toxin-dedicated plant to meet rising demand. Aiming to start operations next year, it plans to expand its annual production capacity from 5 million vials to 16 million vials.
Yun Jun-su, head of the Nabota Business Division at Daewoong Pharmaceutical, said, "We will grow Nabota into a brand with annual sales of 500 billion won by 2030 through global market expansion and the development of next-generation aesthetic products."